Early Warning System

EIB-20220557

CELLECTIS (IEU TI)

Early Warning System
CELLECTIS (IEU TI)

EIB-20220557

Quick Facts

Countries	France
Financial Institutions	European Investment Bank (EIB)
Status	Active
Bank Risk Rating	U
Voting Date	2022-12-28
Borrower	Cellectis SA
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Loan Amount (USD)	$ 42.52 million
Project Cost (USD)	$ 196.64 million

Project Description

As stated by the EIB, the promoter is a clinical-stage biopharmaceutical company pioneer in the field of gene editing, deploying core proprietary technologies to develop off-the-shelf immunotherapies for several oncology indications.
The contemplated transaction will support the Company's R&D investments including: (i) development of four proprietary clinical-stage assets, (ii) pre-clinical development of earlier (or early)-stage assets, and (iii) manufacturing of clinical batches.
The EIB financing will contribute to expand the proprietary pipeline of products under development of the Company, which are expected to constitute the backbone of the company's growth in the future. The project will be coordinated from the Company's headquarters located in Paris (France).

Investment Description

- European Investment Bank (EIB)

Private Actors Description

According to Bloomberg, Cellectis SA is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells.

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Cellectis SA	Client	Education and Health

Contact Information

No project contacts available at the time of disclosure.

Client - Cellectis SA:

Address: 8 rue de la Croix Jarry, 75013 Paris
Phone: +33181691600
Website: www.cellectis.com

ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces

Other Related Projects

- EIB-20220306 THEMATIC INNOVATION (INVESTEU VD) PL